KR20090008728A - Quantitative analysis method of pelargonium sidoides syrup or solution - Google Patents
Quantitative analysis method of pelargonium sidoides syrup or solution Download PDFInfo
- Publication number
- KR20090008728A KR20090008728A KR1020070071910A KR20070071910A KR20090008728A KR 20090008728 A KR20090008728 A KR 20090008728A KR 1020070071910 A KR1020070071910 A KR 1020070071910A KR 20070071910 A KR20070071910 A KR 20070071910A KR 20090008728 A KR20090008728 A KR 20090008728A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- solution
- parts
- pelargonium sidoides
- absorbance
- Prior art date
Links
- 241000756012 Pelargonium sidoides Species 0.000 title claims abstract description 34
- 238000004445 quantitative analysis Methods 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims abstract description 9
- 239000006188 syrup Substances 0.000 title abstract description 14
- 235000020357 syrup Nutrition 0.000 title abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 48
- 239000000284 extract Substances 0.000 claims abstract description 40
- 239000000243 solution Substances 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000002835 absorbance Methods 0.000 claims abstract description 19
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims abstract description 18
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000007864 aqueous solution Substances 0.000 claims abstract description 15
- 239000007788 liquid Substances 0.000 claims abstract description 14
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims abstract description 9
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims abstract description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 9
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000012734 epicatechin Nutrition 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 229910000029 sodium carbonate Inorganic materials 0.000 claims abstract description 9
- 239000006228 supernatant Substances 0.000 claims abstract description 9
- 238000012360 testing method Methods 0.000 claims abstract description 8
- 239000012086 standard solution Substances 0.000 claims description 18
- 239000012488 sample solution Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000005119 centrifugation Methods 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 5
- 238000007865 diluting Methods 0.000 claims description 3
- 230000000857 drug effect Effects 0.000 abstract description 2
- 239000010200 folin Substances 0.000 abstract 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 10
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 9
- 241000208181 Pelargonium Species 0.000 description 6
- 235000001671 coumarin Nutrition 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 229960000956 coumarin Drugs 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 241000611773 Pelargonium reniforme Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 206010044008 tonsillitis Diseases 0.000 description 3
- 238000011481 absorbance measurement Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000004775 coumarins Chemical class 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- LPLLVINFLBSFRP-UHFFFAOYSA-N 2-methylamino-1-phenylpropan-1-one Chemical compound CNC(C)C(=O)C1=CC=CC=C1 LPLLVINFLBSFRP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000132539 Cosmos Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- -1 INF-β Chemical compound 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 241001490312 Lithops pseudotruncatella Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 101100341123 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) IRA2 gene Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/04—Investigating sedimentation of particle suspensions
- G01N15/042—Investigating sedimentation of particle suspensions by centrifuging and investigating centrifugates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
Landscapes
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
도 1은 페라고늄 시도이데스 추출물의 농도와 흡광도와의 관계를 나타낸 그래프이다.1 is a graph showing the relationship between the concentration and absorbance of the Pelargonium sidoides extract.
본 발명은 급성 또는 만성 감염증의 치료제로 사용되는 페라고늄 시도이데스 (Pelargonium sidoides) 추출물을 함유한 시럽 또는 액제의 정량분석법에 관한 것이다.The present invention is used to treat Pelargonium sidoides ( Pelargonium) sidoides ) relates to quantitative analysis of syrups or solutions containing extracts.
남부 아프리카에서 자생하는 페라고늄 시도이데스 및 페라고늄 레니포름(reniforme) 같은 페라고늄 종의 뿌리로부터 추출한 추출물은 설사(diarrhea), 위통(gastrointestinal complaints), 월경불순(dysmenorrhoea), 간질환(liver diseases) 등의 치료제로서 아프리카에서 전통적으로 널리 사용되어 왔다 (Watt,C. (1962) Medicinal and poisonous plants of southern and eastern Africa, Livingstone, Edinburgh, London, S. 449-455). 뿐만 아니라, 호흡계 질환, 특히 결핵(tuberculosis)에 대한 치료에 탁월한 것으로 알려져 있다.Extracts derived from the roots of the species of pelargonium , such as Pelargonium sidoides and Pelargonium reniforme, are found in southern Africa. as a therapeutic agent for liver diseases, etc. (Watt, C. (1962) Medicinal and poisonous plants of southern and eastern Africa , Livingstone, Edinburgh, London, S. 449-455). In addition, it is known to be excellent for the treatment of respiratory diseases, especially tuberculosis.
애초 남아프리카에서 전통 약재로 사용되는 것으로 알려진 페라고늄 시도이데스 추출물는 그 밖의 지역, 구체적으로 칠레 중부나 멕시코 등지에서도 약재로 사용된 것으로 알려지고 있다. 즉, 상기 지역에서는 페라고늄 시도이데스의 추출물이 가진 수렴기능을 이용하여, 설사나 각종 위장 관련 증후군의 처치에 사용하였다. 이들 효과는 상기 추출물의 구성 성분인 탄닌(tannin)에 기인하는 것으로 알려졌다 (Jose San Martin,A.(1983) Econom.Bot, 37, 216-227. INI(1994) Atlas de las plantas de la medicina tradicional mexicans (Instituto Nacional Indigenista, Hrsg.) Vol II, Av. Revolucion no 1279, Col. Tiacopac, Mexiko, S. 667 und 950).Pelargonium sidoides extract, originally known as a traditional medicinal herb in South Africa, is known to be used in other regions, specifically in central Chile and Mexico. That is, in the region, the astringent function of the extract of Pelargonium sidoides was used to treat diarrhea and various gastrointestinal syndromes. These effects are known to be attributed to tannin, a constituent of the extract (Jose San Martin, A. (1983) Econom . Bot, 37 , 216-227. INI (1994) Atlas de las plantas de la medicina tradicional mexicans (Instituto Nacional Indigenista, Hrsg.) Vol II, Av.Revolucion no 1279, Col. Tiacopac, Mexiko, S. 667 und 950).
나아가, 20 세기 초반 미국에서도 페라고늄 시도이데스의 뿌리 추출물은 Umckaloabo 라는 이름으로 상기도 (upper airway)에의 감염 (Kauffer,H.J.(1915) Dental Cosmos 57, 1366), 예컨대 비인두염(rhinopharyngitis), 편도선염(tonsillitis), 정맥두염(sinusitis), 기관지염(brochitis) 등의 치료에 사용되어 왔다.Furthermore, in the early 20th century in the United States, the root extract of Pelargonium sidoides is known as Umckaloabo in the upper airway (Kauffer, HJ (1915) Dental Cosmos 57 , 1366), such as rhinopharyngitis, tonsillitis It has been used in the treatment of tonsillitis, sinusitis, brochitis and the like.
이러한 효과는 페라고늄 시도이데스 추출물의 항미생물 효과에 기인하는 것으로 알려져 있다.This effect is known to be due to the antimicrobial effect of Pelargonium sidoides extract.
보다 자세하게는, 쿠마린 실험을 통해 GLC4, 폐암세포 및 COLO320 세포에 대항하는 중등도의 세포독성이 있음을 알 수 있으며, 이러한 세포독성 효과는 방향성 고리에서의 치환기의 성질과 위치에 전적으로 의존하는 것으로 나타났다. 그리고, 아가희석시험 (agar dilution test)에서 다양한 그람양성, 그람음성 세균에 대한 항미생물 작용을 위한 쿠마린과 탄닌 화합물의 실험은 중등도의 정균 효과를 나타냈다. 최소억제농도 (Minimal Inhibitory Concentration, MIC) 수치는 200 내지 2000 ㎍/㎖ (쿠마린의 경우), 500 내지 2000 ㎍/㎖ (단량체 탄닌 전구체의 경우)이며, 고도의 항균작용이 있는 쿠마린 3 산화, 4 산화 물질이 대표적이다. 이러한, 명확한 항균작용은 페라고늄 시도이데스의 추출물, 특히 뿌리와 잎의 추출물에서 나타나며, 용매로는 물이 가장 큰 항균효과를 나타낸다. (Kayser,O.(1997) Phenolic constituents of Pelargonium sidiodes DC. and studies of the efficacy of the Umcka plant material (Pelargonium sidiodes DC. and Pelargonium reniforme CURT.) Doctorial dissertion, Berlin Free University.) More specifically, coumarin experiments show that there is moderate cytotoxicity against GLC4, lung cancer cells, and COLO320 cells, and this cytotoxic effect is wholly dependent on the nature and position of the substituents in the aromatic ring. In the agar dilution test, experiments with coumarin and tannin compounds for antimicrobial action against various Gram-positive and Gram-negative bacteria showed moderate bacteriostatic effects. Minimal Inhibitory Concentration (MIC) values range from 200 to 2000 μg / ml (for coumarins) and 500 to 2000 μg / ml (for monomer tannin precursors), with highly antimicrobial coumarin trioxide, 4 Oxidized materials are representative. This clear antimicrobial activity is seen in the extract of Pelargonium sidoides, especially the extracts of roots and leaves, water is the largest antibacterial effect as a solvent. (Kayser, O. (1997) Phenolic constituents of Pelargonium sidiodes DC. and studies of the efficacy of the Umcka plant material ( Pelargonium sidiodes DC. and Pelargonium reniforme CURT .) Doctorial dissertion, Berlin Free University.)
한편, 페라고늄 시도이데스 추출물은 면역 조절 효과에 영향을 미침으로써 급성 또는 만성 감염증의 치료에 유용하다.On the other hand, Pelargonium sidoides extract is useful for the treatment of acute or chronic infectious diseases by affecting the immunomodulatory effect.
구체적으로, 페라고늄 시도이데스 추출물은 TNF-α, INF-β, 나이트릭 옥사이드(nitric oxide, NO) 합성을 증가시키는 것으로 보고되고 있다 (H. Kolodziej et al., Phytomedicine 10 (Suppl. 4), 18-24 (2003)).Specifically, Pelargonium sidoides extract has been reported to increase TNF-α, INF-β, nitric oxide (NO) synthesis (H. Kolodziej et al., Phytomedicine 10 (Suppl. 4) , 18-24 (2003)).
나아가, 페라고늄 시도이데스 추출물에서 유래된 쿠마린(coumarin)은 다양한 실험모델에서 면역자극 효과를 나타내는 것으로 조사되었다. 구체적으로, 세포내 라이쉬마니아(Leishmania) 감염 모델에서, 상기 물질들은 산소 의존적 면역 방어기전에 관련하여 구조 의존적으로 중등도의 작용을 보여 주었으며, 특히 단순 쿠마린에 의해 매개된 NO 생성을 경유한 세포내 감염에 대한 중등도의 방어기전 자극은 산소 생성의 증가 정도에 따라 증가하는 것으로 나타났다. 그리고, 상기 추출물의 또 다른 구성 성분인 갈산 (gallic acid)은 탁월한 유도체로서, 그 활성은 고농도의 산화질소 라디칼에 기인한 것이다. (Kayser,O.(1997) Phenolic constituents of Pelargonium sidiodes DC. and studies of the efficacy of the Umcka plant material (Pelargonium sidiodes DC. and Pelargonium reniforme CURT.) Doctorial dissertion, Berlin Free University.)In addition, coumarin derived from Pelargonium sidoides extract has been shown to exhibit immunostimulatory effects in various experimental models. Specifically, in the intracellular Leishmania infection model, these substances showed moderately structure-dependent actions in relation to oxygen-dependent immune defense mechanisms, in particular intracellular infection via NO-mediated NO production mediated by simple coumarins. Moderate defensive stimulation of ROS increases with increasing oxygen production. In addition, gallic acid (gallic acid), which is another component of the extract, is an excellent derivative, and its activity is due to a high concentration of nitric oxide radicals. (Kayser, O. (1997) Phenolic constituents of Pelargonium sidiodes DC. and studies of the efficacy of the Umcka plant material ( Pelargonium sidiodes DC. and Pelargonium reniforme CURT .) Doctorial dissertion, Berlin Free University.)
이러한 페라고늄 시도이데스 추출물은 현재 급성 또는 만성 감염증, 특히 기관지염, 부비강염, 편도염, 비인두염 등의 호흡기계 또는 이비인후 부위의 감염증에 그 효과가 확인되었다.These pelargonium sidoides extracts have been shown to be effective in acute or chronic infections, especially infections of the respiratory tract or ear throat, such as bronchitis, sinusitis, tonsillitis, nasopharyngitis.
한편, 시럽(syrup)제나 액제는 정제를 삼킬 능력이 부족한 어린이나 노약자에게 투여하기가 용이하고, 정제에 비하여 약물효과가 신속히 나타나며, 정제 투여시 개체의 약물 용해도 차이에 의해 야기될 수 있는 생체이용율 차이도 줄여줄 수 있어 약효가 일정하게 유지될 수 있는 장점이 있다. 특히 시럽제의 경우, 경구 투여시 약물에 의한 쓴 맛 및 불쾌한 냄새를 획기적으로 개선할 수 있어, 환자들의 약에 대한 순응도가 높아져 소아나 노인들에게도 쉽게 투여할 수 있다.On the other hand, syrups or solutions are easy to administer to children or the elderly who lack the ability to swallow tablets, have a rapid drug effect compared to tablets, and bioavailability that may be caused by differences in drug solubility in tablets when administered. It can also reduce the difference has the advantage that the drug can be kept constant. In particular, in the case of syrups, oral administration can significantly improve the bitter taste and unpleasant odor caused by the drug, and the patient's compliance with the drug can be improved, so that it can be easily administered to children or the elderly.
그러나, 페라고늄 시도이데스 추출물을 함유한 시럽 또는 액제의 경우, 약효 발현을 담당하는 상기 추출물의 함량 분석법이 확립되어 있지 않아, 실제 적용에 장애가 되어 왔다.However, in the case of syrups or liquid preparations containing the Pelargonium sidoides extract, the content analysis method of the extract responsible for the expression of efficacy has not been established, which has hindered practical application.
본 발명은 상기와 같은 문제점을 해결하기 위하여 안출된 것으로서, 페라고늄 시도이데스 추출물을 함유한 시럽 또는 액제에 있어서, 약효 발현을 담당하는 상기 추출물의 함량을 나타내는 정량분석법을 제공하는 것을 그 목적으로 한다.The present invention has been made to solve the above problems, in the syrup or liquid formulation containing the Pelargonium sidoides extract, to provide a quantitative analysis method showing the content of the extract responsible for the expression of the drug do.
본 발명의 페라고늄 시도이데스 추출물의 정량분석법은 상술한 바와 같은 목적을 달성하기 위하여,하기 단계를 포함하는 것을 특징으로 한다: The quantitative analysis of Pelargonium sidoides extract of the present invention is characterized in that it comprises the following steps in order to achieve the object as described above:
(A) 페라고늄 시도이데스 추출액 1 중량부 당, 15 내지 30 중량%의 에탄올수용액 40 내지 60 중량부, 폴린 시오칼테우스 페놀 (Floin Ciocalteus phenol) 시약 6 내지 9 중량부, 10 내지 20 중량%의 탄산나트륨수용액 40 내지 60 중량부, 및 물 15 내지 40 중량부를 혼합하고, 상기 혼합액을 원심분리하여 상층액을 검액으로 취하는 검액 조제 단계, (A) 40 to 60 parts by weight of 15 to 30% by weight of ethanol aqueous solution, 6 to 9 parts by weight of Floin Ciocalteus phenol reagent, 10 to 20% by weight, per 1 part by weight of Pelargonium sidoides extract 40 to 60 parts by weight of an aqueous sodium carbonate solution, and 15 to 40 parts by weight of water, and the sample solution preparation step of taking the supernatant as a sample solution by centrifuging the mixed solution,
(B) 에피카테킨(epicatechin) 에탄올수용액 1 중량부 당, 15 내지 30 중량%의 에탄올수용액 8 내지 12 중량부, 폴린 시오칼테우스 페놀 (Floin Ciocalteus phenol) 시약 1 내지 2 중량부, 10 내지 20 중량%의 탄산나트륨수용액 8 내지 12 중량부, 및 물 3 내지 8 중량부를 혼합하고, 상기 혼합액을 원심분리하여 상층액을 표준액으로 취하는 표준액 조제 단계, 및 (B) 8 to 12 parts by weight of 15 to 30% by weight of ethanol aqueous solution, 1 to 2 parts by weight of Floin Ciocalteus phenol reagent, 10 to 20% by weight, per 1 part by weight of
(C) 상기 검액 및 표준액을, 물을 대조액으로 하여 흡광도를 측정하는 단계, 및 (C) measuring the absorbance of the sample solution and the standard solution using water as a control solution, and
(D) 하기 수학식 1에 의해 에피카테킨으로서의 총페놀량을 구하는 단계:(D) calculating the total amount of phenol as epicatechin by the following equation (1):
식 중, Et는 검액의 흡광도이고, Where Et is the absorbance of the test liquid,
Es는 표준액의 흡광도이고, Es is the absorbance of the standard solution,
V는 ㎖ 단위로 측정한 검액의 부피이고, V is the volume of the sample solution measured in ml,
S는 mg 단위로 측정한 표준액의 질량임.S is the mass of the standard solution measured in mg.
또한, 상기 혼합액을 원심분리하기 전에 10 내지 30 분 동안 상온에서 정치하는 단계를 추가로 포함할 수 있다.In addition, the mixture may further include the step of standing at room temperature for 10 to 30 minutes before centrifugation.
또한, 상기 원심분리는 5 내지 20 분 동안 수행하는 것이 바람직하다.In addition, the centrifugation is preferably performed for 5 to 20 minutes.
또한, 상기 흡광도는 720 nm에서 측정하는 것이 바람직하다.In addition, the absorbance is preferably measured at 720 nm.
또한, 상기 15 내지 30 중량%의 에탄올수용액은 95 내지 96 중량%의 에탄올수용액과 물을 1 : 2 내지 5의 부피비로 희석하여 제조한 것이 바람직하다.In addition, the 15 to 30% by weight of the ethanol aqueous solution is preferably prepared by diluting 95 to 96% by weight of ethanol aqueous solution and water in a volume ratio of 1: 2 to 5.
이하, 본 발명의 바람직한 실시예에 대하여 상세히 설명한다. 또한, 하기의 설명에서는 구체적인 구성요소 등과 같은 많은 특정사항들이 개시되어 있는데, 이는 본 발명의 보다 전반적인 이해를 돕기 위해서 제공된 것일 뿐 이러한 특정 사항들 없이도 본 발명이 실시될 수 있음은 이 기술분야에서 통상의 지식을 가진 자에게는 자명하다 할 것이다. 그리고, 본 발명을 설명함에 있어서, 관련된 공지 기능 혹은 구성에 대한 구체적인 설명이 본 발명의 요지를 불필요하게 흐릴 수 있다고 판단되는 경우 그 상세한 설명을 생략한다.Hereinafter, preferred embodiments of the present invention will be described in detail. In addition, in the following description, many specific details such as specific components are disclosed, which are provided to help a more general understanding of the present invention, and it is common in the art that the present invention may be practiced without these specific details. It is self-evident to those who have knowledge of the world. In describing the present invention, when it is determined that a detailed description of a related known function or configuration may unnecessarily obscure the subject matter of the present invention, the detailed description thereof will be omitted.
본 발명의 페라고늄 시도이데스 추출물의 정량분석법은 우선 페라고늄 시도이데스의 추출물을 함유하는 검액 및 이와 비교되는 베이스(base)로서의 표준액을 조제하는 단계로부터 시작된다.The quantitative analysis of the Pelargonium sidoides extract of the present invention begins with the preparation of a sample solution containing the extract of Pelargonium sidoides and a standard solution as a base to be compared thereto.
우선 분석의 대상이 되는 페라고늄 시도이데스 추출액은 그 제형과 관계 없이 상기 페라고늄 시도이데스의 추출액을 포함하는 물질이면 모두 포함되며, 본 발명에서는 특히 상기 추출물을 포함하는 시럽 또는 액제가 더욱 바람직하다.First, all the ferrago sidoides extract to be analyzed is included as long as it is a substance containing the extract of the ferrago sidoides irrespective of its formulation, and in the present invention, a syrup or liquid containing the extract is particularly preferable. Do.
상기 추출액 1 중량부 당, 15 내지 30 중량%의 에탄올수용액 40 내지 60 중량부, 폴린 시오칼테우스 페놀 (Floin Ciocalteus phenol) 시약 6 내지 9 중량부, 10 내지 20 중량%의 탄산나트륨수용액 40 내지 60 중량부, 및 물 15 내지 40 중량부를 혼합한다.40 to 60 parts by weight of 15 to 30% by weight of an ethanol aqueous solution, 6 to 9 parts by weight of a Floin Ciocalteus phenol reagent, and 10 to 20% by weight of an aqueous sodium carbonate solution of 40 to 60 parts by weight of the extract Parts and 15 to 40 parts by weight of water are mixed.
여기서, 상기 15 내지 30 중량%의 에탄올수용액은 95 내지 96 중량%의 에탄올수용액과 물을 1 : 2 내지 5의 부피비로 희석하여 제조하는 것이 바람직하다.Here, the 15 to 30% by weight of ethanol aqueous solution is preferably prepared by diluting 95 to 96% by weight of ethanol aqueous solution and water in a volume ratio of 1: 2 to 5.
상기 혼합액은 그 다음 원심분리하고 나서, 그 상층액을 검액으로 취한다.The mixed solution is then centrifuged and the supernatant taken as the sample solution.
이때 상기 원심분리는 5 내지 20 분 동안 수행하는 것이 바람직하다.At this time, the centrifugation is preferably performed for 5 to 20 minutes.
특히, 본 발명에서는 상기 혼합액을 원심분리하기 전에 10 내지 30 분 동안 상온에서 정치하는 단계를 추가로 포함하는 것이 분석결과의 재현성 향상 측면에서 더욱 바람직하다.In particular, in the present invention, it is more preferable to further include the step of leaving the mixture at room temperature for 10 to 30 minutes before centrifugation in terms of improving the reproducibility of the analysis results.
상기 검액과 별도로 에피카테킨(epicatechin) 표준액을 조제한다. 우선, 에피카테킨을 상기 15 내지 30 중량%의 에탄올수용액으로 적당히 희석한 에피카테킨 에탄올수용액 1 중량부 당, 15 내지 30 중량%의 에탄올수용액 8 내지 12 중량부, 폴린 시오칼테우스 페놀 시약 1 내지 2 중량부, 10 내지 20 중량%의 탄산나트륨수용액 8 내지 12 중량부, 및 물 3 내지 8 중량부를 혼합한다.The epicatechin standard solution is prepared separately from the sample solution. First, 8 to 12 parts by weight of 15 to 30% by weight of an ethanol aqueous solution of 15 to 30% by weight of the epicatechin ethanol solution of moderately diluted epicatechin with 15 to 30% by weight of ethanol solution, 1 to 2 parts by weight of a polline sycartheus phenol reagent , 8 to 12 parts by weight of an aqueous 10-20% by weight sodium carbonate solution, and 3 to 8 parts by weight of water.
이후, 정치 단계 및 원심분리 단계는 상기 검액 조제 단계에서와 동일하다.Thereafter, the stationary step and the centrifugation step are the same as in the sample preparation step.
그 다음, 상기 조제된 검액 및 표준액을, 물을 대조액으로 하여 흡광도를 측정하게 되는데, 측정 파장은 720 nm에서 수행하는 것이 가장 바람직하다.Then, the absorbance is measured by using the prepared sample solution and the standard solution as the control solution, the measurement wavelength is most preferably carried out at 720 nm.
마지막으로, 페라고늄 시도이데스 추출액의 함량은 하기 수학식 1에 의해 에피카테킨으로서의 총페놀량을 구함으로써 결정된다:Finally, the content of Pelargonium sidoides extract is determined by calculating the total amount of phenol as epicatechin by the following equation:
[수학식 1][Equation 1]
식 중, Et는 검액의 흡광도이고, Where Et is the absorbance of the test liquid,
Es는 표준액의 흡광도이고, Es is the absorbance of the standard solution,
V는 ㎖ 단위로 측정한 검액의 부피이고, V is the volume of the sample solution measured in ml,
S는 mg 단위로 측정한 표준액의 질량임.S is the mass of the standard solution measured in mg.
이하, 본 발명의 실시예에 대하여 설명한다.EMBODIMENT OF THE INVENTION Hereinafter, the Example of this invention is described.
실시예Example
실시예Example 1: One: 검액Sample 조제 pharmacy
페라고늄 시도이데스 추출물을 포함한 시럽 200 ㎕, 96 중량%의 에탄올수용액을 증류수와 1 : 3으로 혼합·희석한 에탄올 희석액 10 ㎖, 폴린 시오칼테우스 페놀 시약 1.5 ㎖, 탄산나트륨 수용액 10 ㎖를 25 ㎖ 용량의 플라스크에 정취하고, 증류수를 가하여 전량을 25 ㎖로 하였다. 이 혼합액을 20 분 동안 상온에서 정치한 후, 10 분 동안 원심분리하고, 그 상층액을 취하여 검액으로 했다.A mixture of 200 μl of syrup containing Pelargonium sidoides extract and 96% by weight of ethanol solution was mixed with distilled water and 1: 3. The flask was charged with a volume of distilled water, and distilled water was added to make the whole amount 25 ml. The mixture was left at room temperature for 20 minutes, then centrifuged for 10 minutes, and the supernatant was taken as a sample solution.
실시예Example 2: 표준액 조제 2: Standard Solution
에피카테킨 10 mg을 정취하여 20 ㎖ 용량의 플라스크에 넣고, 96 중량%의 에탄올수용액을 증류수와 1 : 3으로 혼합·희석한 에탄올 희석액을 가하여 전량을 20 ㎖로 하였다. 상기 용액 1 ㎖를 취하여 상기 에탄올 희석액을 다시 가하여 전량을 10 ㎖로 만든 다음 여기서 1 ㎖를 취했다. 상기 마지막으로 취한 용액 1 ㎖, 상기 에탄올 희석액 10 ㎖, 폴린 시오칼테우스 페놀 시약 1.5 ㎖, 탄산나트륨 수용액 10 ㎖를 25 ㎖ 용량의 플라스크에 정취하고, 증류수를 가하여 전량을 25 ㎖로 하였다. 이 혼합액을 20 분 동안 상온에서 정치한 후, 10 분 동안 원심분리하고, 그 상층액을 취하여 표준액으로 했다.10 mg of epicatechin was collected and placed in a 20 ml flask, and 96% by weight of an ethanol solution was mixed with distilled water and diluted 1: 3 to dilute ethanol dilutions to make the total amount 20 ml. 1 ml of the solution was taken and the distillation of the ethanol was added again to make 10 ml of the total amount, where 1 ml was taken. 1 ml of the last solution taken, 10 ml of the ethanol dilution solution, 1.5 ml of a Pauline Siaceticus phenol reagent, and 10 ml of an aqueous sodium carbonate solution were rinsed into a 25 ml flask, and distilled water was added to make 25 ml. The mixture was left at room temperature for 20 minutes, then centrifuged for 10 minutes, and the supernatant was taken as a standard solution.
실시예Example 3: 흡광도 측정 (1) 3: Absorbance Measurement (1)
상기 실시예 1의 검액 및 실시예 2의 표준액을, 물을 대조액으로 하여 총장 10 mm, 파장 720 nm에서 흡광도 (Agilent 사. 모델 8453)를 측정하였다. 상기 측정은 5 회 반복하였고, 그 결과를 표 1에 나타내었다.In the sample solution of Example 1 and the standard solution of Example 2, absorbance (Agilent. Model 8453) was measured at a total length of 10 mm and a wavelength of 720 nm using water as a control solution. The measurement was repeated five times and the results are shown in Table 1.
측정 결과, 상기 표 1에 나타난 바와 같이 상대표준편차 1.14로 높은 수준의 재현성을 보였다.As a result of the measurement, a high level of reproducibility was shown with a relative standard deviation of 1.14.
실시예Example 4: 흡광도 측정 (2) 4: absorbance measurement (2)
상기 실시예 3을 반복하되, 상기 실시예 1의 페라고늄 시도이데스 추출물을 포함한 시럽의 양을 50, 80, 100, 150, 200 ㎕로 달리해 가며 측정하였다. 그 결과를 표 2 및 도 1에 나타내었다.The Example 3 was repeated, but the amount of syrup containing the Pelargonium sidoides extract of Example 1 was measured by varying 50, 80, 100, 150, 200 μl. The results are shown in Table 2 and FIG.
측정 결과, 상관 계수 0.99973의 높은 직선성을 확인할 수 있어, 최소한 상기 농도 범위에서는 농도와 흡광도 사이에 비례관계가 성립함을 이용할 수 있다.As a result of the measurement, a high linearity of the correlation coefficient 0.99973 can be confirmed, and at least in the above concentration range, a proportional relationship between concentration and absorbance can be used.
이상에서는 본 발명의 바람직한 실시예에 대해서 도시하고 설명하였으나, 본 발명은 상술한 특정의 실시예에 한정되지 아니하며, 당해 기술분야에서 통상의 지식을 가진 자라면 본원 발명의 요지를 벗어남이 없이 다양한 변형 실시가 가능함은 물론이다. 따라서, 본 발명의 범위는 위의 실시예에 국한해서 해석되어서는 안되며, 후술하는 특허청구범위 뿐만 아니라 이 특허청구범위와 균등한 것들에 의해 정해져야 할 것이다.Although the above has been illustrated and described with respect to the preferred embodiments of the present invention, the present invention is not limited to the specific embodiments described above, those skilled in the art without departing from the gist of the present invention various modifications Of course, implementation is possible. Therefore, the scope of the present invention should not be construed as being limited to the above embodiments, but should be defined by the claims below and equivalents thereof.
본 발명의 페라고늄 시도이데스 추출물을 함유한 시럽 또는 액제의 정량분석법으로 인해, 상기 시럽 또는 액제에서 페라고늄 시도이데스 추출물의 함량 측정을 통한 품질관리 및 약리효과 발현 보장이 가능하게 되었으며, 상기 분석법은 비교적 간단한 조작을 통해, 재현성이 뛰어나고 높은 신뢰도를 보이는 장점을 가지고 있다.Due to the quantitative analysis of the syrup or solution containing the Pelargonium sidoides extract of the present invention, it is possible to ensure the quality control and pharmacological effect expression by measuring the content of the Pelargonium sidoides extract in the syrup or solution, The analysis method has the advantage of excellent reproducibility and high reliability through relatively simple operation.
Claims (5)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070071910A KR20090008728A (en) | 2007-07-18 | 2007-07-18 | Quantitative analysis method of pelargonium sidoides syrup or solution |
PCT/KR2008/003514 WO2009011499A1 (en) | 2007-07-18 | 2008-06-20 | Quantitative analysis method of pelargonium sidoides syrup or solution |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070071910A KR20090008728A (en) | 2007-07-18 | 2007-07-18 | Quantitative analysis method of pelargonium sidoides syrup or solution |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20090008728A true KR20090008728A (en) | 2009-01-22 |
Family
ID=40259802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070071910A KR20090008728A (en) | 2007-07-18 | 2007-07-18 | Quantitative analysis method of pelargonium sidoides syrup or solution |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20090008728A (en) |
WO (1) | WO2009011499A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102216470B1 (en) | 2013-11-01 | 2021-02-17 | 주식회사 클라시아 | Composition of Natural Substance |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1429795B1 (en) * | 2001-09-27 | 2007-06-13 | Dr. Willmar Schwabe GmbH & Co. KG | Method for producing extracts of pelargonium sidoides and/or pelargonium reniforme |
-
2007
- 2007-07-18 KR KR1020070071910A patent/KR20090008728A/en not_active Application Discontinuation
-
2008
- 2008-06-20 WO PCT/KR2008/003514 patent/WO2009011499A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2009011499A1 (en) | 2009-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kokoska et al. | Plant-derived products as antibacterial and antifungal agents in human health care | |
KR100896453B1 (en) | Pelargonium sidoides Syrup | |
Castro | Propolis: biological and pharmacological activities. Therapeutic uses of this bee-product | |
Wittpahl et al. | The polyphenolic composition of Cistus incanus herbal tea and its antibacterial and anti-adherent activity against Streptococcus mutans | |
Chauhan et al. | A review: Nutraceuticals properties of Piper betel (Paan) | |
TR201722959A2 (en) | Solid oral formulations comprising herbal extracts | |
Di Fabio et al. | Gymnema sylvestre R. Br., an Indian medicinal herb: traditional uses, chemical composition, and biological activity | |
KL Shanbhag | Triphala in prevention of dental caries and as an antimicrobial in oral cavity-a review | |
Farag et al. | Salvadora persica L.: Toothbrush tree with health benefits and industrial applications–An updated evidence-based review | |
CN113332244B (en) | Antiviral oral spray and preparation method thereof | |
Kale et al. | In vitro anthelmintic activity of stem bark of Juglans regia L | |
Nazliniwaty et al. | Formulation and antibacterial activity of plectranthus amboinicus (Lour.) spreng leaves ethanolic extract as herbal mouthwash against halitosis caused bacteria | |
RU2412718C1 (en) | Medication for treatment and prevention of acute respiratory viral and bacterial diseases and method of obtaining it | |
Jadhao et al. | Formulation and evaluation of herbal syrup | |
Harini et al. | Antioxidant activity (phenol and flavonoid content) of three different cultivars of piper betle l.(piperaceae) | |
Sankarganesh et al. | Phytomedicinal chemistry and pharmacognostic value of Carica papaya L., leaf | |
Rathi et al. | Pharmaceutico-analytical standardization of triphala mouthwash | |
KR20090008728A (en) | Quantitative analysis method of pelargonium sidoides syrup or solution | |
Tchoumba Tchoumi et al. | Antimicrobial and antidiarrhoeal activities of aqueous and methanolic extracts of Mangifera indica Linn stem bark (Anarcadiaceae) in Wistar rats | |
Subhan | Phytochemical and pharmacological investigations of Australian Acacia: an ethnomedicine-guided bioprospective approach | |
JP2012067065A (en) | Anti-periodontic disease medicine | |
Singh et al. | Standardization of modified dosage form of Lodhradi Kashaya prepared by two different techniques | |
Bhatnagar | A comprehensive review of kalmegh’s biological activities (Andrographis paniculata) | |
Waghmare et al. | Anti-anaemic potential of Murraya koenigii fruit extracts in phenylhydrazine induced anaemic rats | |
Thalkari et al. | Cissus quadrangularis: A Natural Booster |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
N231 | Notification of change of applicant | ||
E90F | Notification of reason for final refusal | ||
E601 | Decision to refuse application |